Subscribe To
OVID / Ovid Therapeutics (OVID) Upgraded to Buy: Here's What You Should Know
OVID News
By GlobeNewsWire
September 20, 2023
Ovid Therapeutics to Present at the 2023 Cantor Fitzgerald Global Healthcare Conference
NEW YORK, Sept. 20, 2023 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that more_horizontal
By Zacks Investment Research
August 4, 2023
Ovid Therapeutics (OVID) Reports Q2 Loss, Lags Revenue Estimates
Ovid Therapeutics (OVID) came out with a quarterly loss of $0.18 per share versus the Zacks Consensus Estimate of a loss of $0.21. This compares to lo more_horizontal
By Seeking Alpha
June 13, 2023
Ovid Therapeutics: Bullish Outlook Strengthened By Positive 2-Year Open-Label Trial Results
Ovid Therapeutics' TAK-935 has a high potential for positive Phase 3 clinical trial results for both Dravet Syndrome (DS) and Lennox-Gastaut Syndrome more_horizontal
By Zacks Investment Research
May 5, 2023
Ovid Therapeutics (OVID) Reports Q1 Loss, Tops Revenue Estimates
Ovid Therapeutics (OVID) came out with a quarterly loss of $0.19 per share versus the Zacks Consensus Estimate of a loss of $0.18. This compares to lo more_horizontal
By Zacks Investment Research
April 12, 2023
Ovid Therapeutics (OVID) Upgraded to Buy: Here's What You Should Know
Ovid Therapeutics (OVID) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy more_horizontal